Altamira Therapeutics to Participate at RNA Leaders USA

HAMILTON, BERMUDA , Oct. 13, 2022 (GLOBE NEWSWIRE) —

• Event will be held on October 18-19, 2022 in Boston, MA
• Samuel Wickline, MD, Chief Scientific Officer, to present on the advantages of the OligoPhore/SemaPhore technology, a versatile peptide-based delivery platform for extrahepatic RNA delivery
• The event will provide the Company the opportunity to present its innovative delivery platform and engage with RNA community in science and industry

Altamira Therapeutics Ltd. (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it will participate in-person at the RNA Leaders USA Congress being held on October 18-19, 2022 at The Colonnade Hotel in Boston, Massachusetts.   

Altamira’s Chief Scientific Officer, Samuel A. Wickline, MD, will be introducing the Company’s flagship OligoPhore/ SemaPhore delivery platform and address the following aspects and advantages of siRNA therapeutics that differentiate the Company’s technology:

• Universal formulation process for any RNA species, single or multiplexed to address one or more signaling pathways simultaneously
• Systemic administration achieving extrahepatic delivery to diverse pathologies, but excluding permeation of normal tissues to limit off-target effects
• Deep penetration into tumor and inflammatory microenvironment
• Extensive and rapid pH-dependent endosomal escape of RNA cargo to promote immediate RNA silencing or enhanced protein expression as needed
• Minimize tissue toxicity and immune reactivity after serial dosing in a multiplicity of disease models
• Adaptable to diverse pathologies with readily exchangeable RNA cargos to counter adaptive disease responses

Altamira aims to become a leading provider of RNA delivery technology through its patented OligoPhore/SemaPhore platform, which it seeks to out-license to biotech and pharma companies for use with their own RNA molecules. In addition, the Company is progressing two internal…